[{"address1": "30 Worcester Road", "city": "Toronto", "state": "ON", "zip": "M9W 5X2", "country": "Canada", "phone": "416 798 3001", "website": "https://www.intellipharmaceutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.", "fullTimeEmployees": 11, "companyOfficers": [{"maxAge": 1, "name": "Dr. Isa  Odidi MBA, Ph.D.", "age": 65, "title": "Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 347941, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amina  Odidi Ph.D.", "age": 63, "title": "President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 347941, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick N. Yat Ph.D.", "age": 65, "title": "Vice-President of Chemistry & Analytical Services", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 119929, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Fazayill  Shaideen", "title": "Controller", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.05, "open": 0.07, "dayLow": 0.055, "dayHigh": 0.08, "regularMarketPreviousClose": 0.05, "regularMarketOpen": 0.07, "regularMarketDayLow": 0.055, "regularMarketDayHigh": 0.08, "beta": 0.294, "volume": 78050, "regularMarketVolume": 78050, "averageVolume": 10245, "averageVolume10days": 11670, "averageDailyVolume10Day": 11670, "marketCap": 2647416, "fiftyTwoWeekLow": 0.01, "fiftyTwoWeekHigh": 0.11, "priceToSalesTrailing12Months": 2.925496, "fiftyDayAverage": 0.055, "twoHundredDayAverage": 0.06215, "currency": "USD", "enterpriseValue": 4465621, "floatShares": 32511227, "sharesOutstanding": 33092700, "sharesShort": 713995, "sharesShortPriorMonth": 211757, "sharesShortPreviousMonthDate": 1548892800, "dateShortInterest": 1551312000, "sharesPercentSharesOut": 0.0326, "heldPercentInsiders": 0.01757, "shortRatio": 0.39, "shortPercentOfFloat": 0.0335, "impliedSharesOutstanding": 38895700, "bookValue": -0.389, "lastFiscalYearEnd": 1669766400, "nextFiscalYearEnd": 1701302400, "mostRecentQuarter": 1693440000, "netIncomeToCommon": -3173811, "trailingEps": -0.09, "lastSplitFactor": "1:10", "lastSplitDate": 1536883200, "enterpriseToRevenue": 4.935, "enterpriseToEbitda": -1.855, "52WeekChange": 0.6, "SandP52WeekChange": 0.29191303, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IPCIF", "underlyingSymbol": "IPCIF", "shortName": "INTELLIPHARMACEUTICS INTL INC", "longName": "Intellipharmaceutics International Inc.", "firstTradeDateEpochUtc": 1256563800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5df9ea02-19b7-3f49-a70b-d1a637e4a17d", "messageBoardId": "finmb_23127248", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.08, "recommendationKey": "none", "totalCash": 400102, "totalCashPerShare": 0.012, "ebitda": -2407400, "totalDebt": 2218310, "quickRatio": 0.046, "currentRatio": 0.06, "totalRevenue": 904946, "revenuePerShare": 0.025, "returnOnAssets": -1.07386, "freeCashflow": 1067963, "operatingCashflow": 120453, "revenueGrowth": 2.604, "grossMargins": 0.47412997, "ebitdaMargins": -2.66027, "operatingMargins": -26.010239, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-27"}]